NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in ...
What’s Going On with PSTX Stock? News of the acquisition has sent PSTX stock surging this morning. Shares have skyrocketed 225% since markets opened, and they are showing no signs of slowing down.
On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis. The deal consideration ...
Poseida Therapeutics Inc. is being bought out for $1.5 billion by partner Roche Holdings Inc. to allogeneic CAR T therapies to treat hematologic malignancies. The two companies began their ...
Poseida Therapeutics (NASDAQ:PSTX) just reported results for the second quarter of 2024. Poseida Therapeutics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of ...
Update 9:40 PM EST: Adds comments from Poseida. Shares of Poseida Therapeutics (NASDAQ:PSTX) traded higher on Wednesday after the U.S. Food and Drug Administration (FDA) granted its orphan drug ...
Poseida Therapeutics, Inc. (PSTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates - ...
To the annoyance of some shareholders, Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares are down a considerable 44% in the last month, which continues a horrid run for the company. Instead of being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results